Replies to post #39678 on $heff's $tation of $tocks & $olid DD

[nywest329]

PLX at NHOD 10.15

[$heff]

PLX $10.18...Pfizer has the PLX drug front and center as part of its growth strategy in the coming years. Unlike ABT with DEPO, PFE has been committed to this relationship in the development of the PLX drug for Gaucher's Disease. Thanks Stock H.O.G for the link to the pipeline.
http://www.pfizer.com/files/research/pipeline/2010_0927/pipeline_2010_0927.pdf




Stock H.O.G comments:

PLX - unlike ABT w/DEPO, Pfizer does have PLX's drug mentioned on their website....see page 10 of 22

In addition, Pfizer has global (except Israel) rights to Taliglucerase alfa. Anything is possible, but I feel that this relationship is on sturdy ground, so I don't think we'll see a repeat of what we just went through with ABT/DEPO.

[Driven]

PLX taking a dip, here comes the potential opportunity! :)